Blue Owl Capital Invests up to $262.5 Million in ITM Isotope Technologies Munich SE

Washington, DC – May 27, 2025 – Cooley advised Blue Owl Capital (NYSE: OWL), an asset manager redefining alternatives, on an up to $262.5 million term loan facility for ITM Isotope Technologies Munich SE, a radiopharmaceutical biotech company dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors.

Partners Michael Tollini and Addison Pierce led the interdisciplinary Cooley team advising Blue Owl, which also included patent counseling and prosecution partner Jonathan Cousin, life sciences partner Geoffrey Spolyar, tax partner Xander Lee and life sciences and healthcare regulatory partner Phil Mitchell.

Cooley previously advised Blue Owl on its $250 million debt financing with TG Therapeutics in August 2024, its up to $1.05 billion investment in BridgeBio Pharma in January 2024, and its $140 million investment in XOMA Corporation in December 2023.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.